Publication: Nalidixic acid surrogate test for susceptibility to ciprofloxacin in Salmonella. Revisiting the question.
dc.contributor.author | Guzmán-Martín, José Luis | |
dc.contributor.author | Navarro-Marí, José María | |
dc.contributor.author | Expósito-Ruiz, Manuela | |
dc.contributor.author | Gutiérrez-Fernández, José | |
dc.date.accessioned | 2023-01-25T10:09:03Z | |
dc.date.available | 2023-01-25T10:09:03Z | |
dc.date.issued | 2018 | |
dc.description.abstract | We investigated the reliability of nalidixic acid (NA) susceptibility as a marker of ciprofloxacin susceptibility in Salmonella, analysing 302 stool isolates. NC53 of the MicroScan system was used for NA susceptibility tests and the E-test was used for ciprofloxacin susceptibility tests. Among the isolates, 178 (58.9 %) were serogroup B, 74 (24.5 %) were serogroup D, 27 (8.9 %) were serogroup C and 23 (7.6 %) were from other minor serogroups. Globally, susceptibility to NA correctly predicted the susceptibility of Salmonella to ciprofloxacin, with a sensitivity of 81.5 %, a specificity of 97.6 %, and positive and negative predictive values of 88 and 96 %, respectively. However, there were differences among the serogroups in terms of sensitivity (P | |
dc.identifier.doi | 10.1099/jmm.0.000755 | |
dc.identifier.essn | 1473-5644 | |
dc.identifier.pmid | 29767616 | |
dc.identifier.unpaywallURL | https://doi.org/10.1099/jmm.0.000755 | |
dc.identifier.uri | http://hdl.handle.net/10668/12474 | |
dc.issue.number | 7 | |
dc.journal.title | Journal of medical microbiology | |
dc.journal.titleabbreviation | J Med Microbiol | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen de las Nieves | |
dc.organization | Fundación Pública Andaluza para la Investigación Biosanitaria en Andalucía Oriental-Alejandro Otero-FIBAO | |
dc.page.number | 965-967 | |
dc.pubmedtype | Journal Article | |
dc.rights.accessRights | open access | |
dc.subject | Salmonella | |
dc.subject | ciprofloxacin | |
dc.subject | enteritis | |
dc.subject | nalidixic acid | |
dc.subject | stools | |
dc.subject.mesh | Anti-Bacterial Agents | |
dc.subject.mesh | Ciprofloxacin | |
dc.subject.mesh | Drug Resistance, Bacterial | |
dc.subject.mesh | Feces | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Microbial Sensitivity Tests | |
dc.subject.mesh | Nalidixic Acid | |
dc.subject.mesh | Salmonella | |
dc.subject.mesh | Salmonella Infections | |
dc.subject.mesh | Serogroup | |
dc.title | Nalidixic acid surrogate test for susceptibility to ciprofloxacin in Salmonella. Revisiting the question. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 67 | |
dspace.entity.type | Publication |